NDAORAL-28TABLET
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORLESTRIN FE 1/50 is a combination oral contraceptive containing norethindrone acetate (progestin), ethinyl estradiol (estrogen), and ferrous fumarate (iron supplement). It prevents pregnancy through hormonal contraception while providing iron supplementation to offset menstrual blood loss. The iron component is included in the 7-day hormone-free interval to maintain compliance and reduce anemia risk.
PRE_LAUNCH
Pre-launch stage signals active commercial team buildout for field sales, marketing, and market access roles ahead of anticipated market entry.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NORLESTRIN FE 1/50 offers pre-launch exposure in a competitive contraceptive market with a Tier-1 sponsor (Pfizer), building commercial execution and competitive positioning skills. Career trajectory depends heavily on post-launch performance; success in a saturated market requires differentiation strategy and competitive intelligence.
Brand ManagerProduct Manager
Worked on NORLESTRIN FE 1/50 at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.